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t Université de Lyon, F-69000, Lyon, France 
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There is a great deal of debate on the question of whether or not we know what ageing is (Ref. Cohen et al., 
2020). Here, we consider what we believe to be the especially confused and confusing case of the ageing of the 
human immune system, commonly referred to as “immunosenescence”. But what exactly is meant by this term? 
It has been used loosely in the literature, resulting in a certain degree of confusion as to its definition and im-
plications. Here, we argue that only those differences in immune parameters between younger and older adults 
that are associated in some definitive manner with detrimental health outcomes and/or impaired survival 
prospects should be classed as indicators of immunosenescence in the strictest sense of the word, and that in 
humans we know remarkably little about their identity. Such biomarkers of immunosenescence may nonetheless 
indicate beneficial effects in other contexts, consistent with the notion of antagonistic pleiotropy. Identifying 
what could be true immunosenescence in this respect requires examining: (1) what appears to correlate with age, 
though generality across human populations is not yet confirmed; (2) what clearly is part of a suite of canonical 
changes in the immune system that happen with age; (3) which subset of those changes accelerates rather than 
slows aging; and (4) all changes, potentially population-specific, that accelerate agig. This remains an immense 
challenge. These questions acquire an added urgency in the current SARS-CoV-2 pandemic, given the clearly 
greater susceptibility of older adults to COVID-19.   
1. Introduction 
Contributions to this Special Issue of Mech Ageing Dev address the 
outcomes of a recent symposium on the biology of aging asking whether 
or not we know what ageing is (Cohen et al., 2020) and see https://www 
.fourwav.es/view/1393/info/). Regarding this question of what is 
ageing in the specific context of immunity, one thing is clear: it is 
incontrovertible that the human immune system, like any other normal 
somatic tissue, appears to be different in younger and older adults both 
in its architecture, composition and function. Clearly, organisms must 
display changes to many phenotypic traits across developmental and 
later life-history stages that are age-associated but not necessarily 
senescence. Some of these changes, perhaps especially those seen in the 
immune system, are the result of the execution of a life-history strategy 
that has been shaped by both natural and sexual selection (Schmid--
Hempel, 2003). Under the umbrella term “immunosenescence”, certain 
changes to immunity are believed to result in an increased susceptibility 
to, and severity of, infectious disease and to contribute to many or 
perhaps all non-communicable age-associated diseases, among them 
neoplasia, cardiovascular disease, and autoimmunity. It is proposed that 
understanding these events can be best achieved in the context of the 
exertion of evolutionary pressures. Newborns have a naïve immune 
system that must rapidly recognize and respond to the myriad of path-
ogens in the environment, overcome all these challenges and develop 
protective immunity to those most commonly present in the locality. 
There is thus an immediate potent selective pressure, reflected in the 
large investment of resources in immunity throughout childhood. The 
amount of resources required to develop and maintain efficient immune 
responses under excessive pathogen pressure may need to be so large to 
ensure survival that it can result in significant growth retardation 
(Urlacher et al., 2018). Such negative associations between immuno-
competence and growth have been described in a wide range of species 
and ecological conditions (e.g. in wild populations of vertebrates (Soler 
et al., 2003; Palacios et al., 2020) as well as modern hunter-gatherers or 
forager-horticulturists (Urlacher et al., 2018)). Those individuals sur-
viving the local pathogen onslaught will have developed protective 
adaptive immunity by the time of sexual maturity and are thus better 
equipped by virtue of the genes that ensured their survival to face the 
local pathogen environment so that when they reproduce, these genes 
are enriched in the population. At puberty, the production of new naïve 
T cells plummets because of the normal developmental (not senescent) 
process of thymic involution (Thomas et al., 2020), and the individual 
then relies predominantly on adaptive immune memory for the preva-
lent local pathogens, with fewer naïve T cells available to respond to 
new pathogen challenges which the individual might never need to face 
(Pawelec, 2018). Therefore, after adulthood and reproduction, there is a 
trade-off between protection against known “tribal” pathogens and the 
investment of resources in the generation of T cells specific for patho-
gens that might never be encountered (and which, apart from being 
resource-intensive also carry the risk of generating autoimmunity). The 
older individual must therefore rely on a minor pool of residual naïve 
cells and a major biased reservoir of accumulated memory cells. 
Unlike adaptive immunity, innate immunity is conserved in both 
vertebrate and invertebrates (Muller et al., 2013), and essentially retains 
functionality or even becomes over-exuberant with age. Within this 
scenario, we would predict that immunosenescence in older humans 
would include low amounts of naïve T and B cells, high numbers of 
memory cells and potentially over-active innate immune cells which 
would need to be assessed in the context of their long-term residence in 
an aged host. Here, we will consider how well the available data in 
humans conform to the expectations of this paradigm. Given the dy-
namic nature of the immune system, distinguishing between adaptive 
responses and changes caused by the ageing process are highly prob-
lematic. To overcome this difficulty, it is proposed that only those dif-
ferences between younger and older individuals that have been robustly 
associated with detrimental health, reproductive and survival outcomes, 
or those for which this is highly likely but not yet proven, should be 
considered as indicators of “senescence” in the exact meaning of the 
word proposed here. There was considerable debate around this issue 
centered around whether certain properties of the immune system 
associated with strict immunosenescence might also manifest under 
other circumstances, analogous to the findings that replicative senes-
cence programs are reported to be essential for tissue remodelling in 
embryogenesis (Munoz-Espin et al., 2013). We propose overcoming this 
mostly semantic problem by employing a similar tactic to the useful 
distinction in population genetics between broad-sense heritability and 
strict-sense heritability (Visscher et al., 2008). Thus, we would need to 
distinguish between 1) Changes in the immune system with age that are 
adaptive for the individual; 2) Changes in the immune system with age 
that may have positive effects on some aspects of health and negative 
effects on others; 3) Changes in the immune system with age that may 
have positive or negative effects under different environmental contexts, 
or in different individuals, and are thus difficult to classify as adaptive or 
detrimental; 4) Changes in the immune system with age that may have 
positive effects at some ages but negative effects at others; 5) Some 
changes with age that are known to have exclusively negative effects on 
health and longevity. In all cases, measurement issues are a major factor, 
and in many instances we do not yet know which age-associated im-
mune changes are assignable to which category. Hence, at this stage, we 
propose that it might be useful to distinguish between 1) Strict, general 
immunosenescence in which age-associated changes have been defined 
as exclusively detrimental; 2) Strict, individual immunosenescence in 
which changes are detrimental within an individual in their particular 
context, even if these are not the same as for others, and even if mea-
surement issues preclude establishing exactly what every one of these 
changes is; 3) Broad immunosenescence (all changes in the immune 
system with age, regardless of whether they are beneficial or not, which 
may be hard to ascertain). 
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This uncertainty about how to define immunosenescence and inter-
pret its significance for health during aging is analogous to a similar 
uncertainty regarding the significance of sarcopenia, anthropometric 
changes and cognitive decline associated with age; are they harbingers 
of frailty and morbidity or not? This part of the argument is being 
actively pursued by the “Immune Ageing Working Group” formed 
recently to discuss the possibility of coding senescence as a recognized 
disease state (Calimport et al., 2019) and currently preparing a position 
paper on this topic. 
2. Where did we stand in 2019? 
A the time of the conference referred to above (https://www.fourw 
av.es/view/1393/info/) it was common to find a dominant paradigm 
in the literature that “declining function of the immune system, termed 
"immunosenescence", leads to a higher incidence of infection, cancer, 
and autoimmune disease related mortalities in the elderly population” to 
cite one common way of introducing the topic (Stahl and Brown, 2015). 
This notion has encouraged numerous attempts by companies and 
academia to find interventions that prevent or reverse it (Faragher et al., 
2014; Capri et al., 2006; Aspinall and Lang, 2018; Aiello et al., 2019). 
First demonstrating which changes of immune ageing are in fact asso-
ciated with detrimental health outcomes and only then trying to restore 
them to an appropriate level may indeed be theoretically desirable. 
However, prior to establishing which are truly detrimental, rather than 
merely different in aged individuals, such intervention would be pre-
mature, and in some cases might be dangerous (Cohen et al., 2019). One 
has to say that with this in mind most such efforts are indeed premature 
because we do not know which parameters to take as biomarkers 
reflecting these changes, and mistakenly attempting to “correct” adap-
tive changes would be undesirable. Hence, there is an argument in 
favour of attempts to classify such biomarkers of senescence in ageing in 
general, and even more challengingly in immunosenescence in partic-
ular, in order to generate actionable entities for treatment (Calimport 
et al., 2019). Hence, ideally, to identify true indicators of immunose-
nescence, confounding factors should be considered when designing the 
experiments, including individual health status, adaptive immunity, and 
ethnic differences, but in practise this is a major challenge in humans. 
So, as alluded to above, a clear definition of the term “immunose-
nescence” is required, if only to distinguish it from the phenomenon that 
most springs to mind for biologists of ageing who are not immunologists. 
Thus, we need to be clear that “immunosenescence” does not refer to the 
cell biological concept of “replicative senescence”, describing the 
“Hayflick Limit” at which somatic human cells cease dividing due to 
telomere attrition (in vitro) (Hayflick, 1968; Harley et al., 1990). It 
rather refers to differences between younger and older individuals, 
sometimes shown to be changes, but most often only assumed to be 
changes, in the output of immune cells from the bone marrow, the dis-
tribution of immune cells in the periphery and their functionality. 
Within populations of different immune cell types it is likely that some 
do exhibit signs of replicative senescence, but the term immunose-
nescence encompasses far more differences. To define immunose-
nescence, it is proposed that only those differences that have been shown 
to be associated with a detrimental clinical outcome (e.g. mortality, 
frailty, poor response to vaccination, etc.) should be included. Thus, it is 
still the case that the majority of published studies documents differ-
ences between older and younger adults but fails to associate these with 
a measurable poor clinical condition or with mortality. Moreover, most 
of the reported differences have not formally been shown to be actual 
changes over time by means of longitudinal studies. Therefore, 
age-specific changes in immune traits within individuals might be 
underestimated in cross-sectional analyses if within a population there is 
a selective disappearance of individuals with low immunocompetence 
(Froy et al., 2019; Vaupel and Yashin, 1985). In addition, patterns 
observed from cross-sectional studies might be mostly attributable to 
numerous differences between birth cohorts from the early-to-mid 20th 
century who are now being compared in cross-sectional studies with 
young controls from the early 21st century (Pawelec, 2019). There have 
been such striking changes in environment, climate, nutrition, educa-
tion, life style and morbidity profile - not to mention advances in med-
icine and public health, including vaccination policies and practices (to 
name but a few factors) in the intervening years, that studies of such 
cohorts are not comparing like with like. Thus, individual immuno-
competence (and associated immunophenotype) will have been driven 
to differ not only across age strata but also within strata owing to in-
equities in health care and other social disparities (Mbow et al., 2014; 
Labuda et al., 2014). It is essentially impossible to control for these 
confounding factors, and for practical reasons earlier longitudinal 
studies mostly focused on following up people already very old, say 85 
years of age, so that health and immunity changes over a few years will 
already be informative for mortality. Such approaches were rare, but 
some pioneering studies including simple immune parameters were 
already ongoing several decades ago, e.g. the Baltimore Longitudinal 
Study of Aging [https://www.nia.nih.gov/research/labs/blsa], the Lei-
den 85-Plus study (von Faber et al., 2001) and the Swedish OCTO and 
later NONA studies (Wikby et al., 1994). These oldest-old populations 
were of course not representative of ageing and mortality of the majority 
of people in those countries’ general population, but at least such 
long-lived selected populations allowed the hypothesis to be tested that 
the immune parameters identified at baseline, and in some studies their 
changes over time, are associated with mortality within a relatively 
short period of time. Since these early studies, several important longi-
tudinal studies have been established using more sophisticated immu-
nological assessments to associate baseline immune parameters, and 
changes thereof over time, with clinical outcomes including not only 
mortality but also more granular clinically-relevant outcomes like re-
sponses to vaccination and frailty/morbidity. Such results, supple-
mented with data from cross-sectional studies identifying differences in 
immune biomarkers between younger and older adults, are finally 
beginning to define immune signatures determining whether a person is 
truly “immunosenescent”. Do we now know what these immune pa-
rameters are and which outcomes we should assess? The following 
sections consider this question. 
3. Where do we stand in 2020? 
A consensus from published studies delineates one immune param-
eter consistently reported to be different between younger and older 
adults, namely the very low absolute and relative counts of naïve CD8+ T 
cells in the peripheral blood of older adults (Fagnoni et al., 2000). This is 
not to say the older adults actually do possess fewer naïve T cells because 
data on the presence of immune cells in other organs are mostly lacking 
and most data pertain only to circulating cells. However, the expectation 
is that the whole-body number of CD8+ naïve T cells is indeed low, due 
to markedly reduced thymic output and cell mortality owing to a life-
time’s exposure to pathogens, agreeing with data from animal models. 
Reciprocally, it would be expected that because antigen-stimulated 
naïve cells differentiate into effector and memory cells, the latter 
would be increased in older adults, as also often reported (Fagnoni et al., 
2000). It is thus somewhat surprising that CD8+ memory cell accumu-
lation in the blood of older adults is not universally reported. It has 
become apparent in the meantime that the accumulations of late-stage 
memory cells that are seen in older people are driven by persistent 
infection with human herpesvirus 5 (HHV5; cytomegalovirus [CMV]), 
but apparently not by other herpesviruses or other pathogens (Derho-
vanessian et al., 2010; Wertheimer et al., 2014; Derhovanessian et al., 
2011). These sometimes disputed findings have been confirmed in sys-
tematic reviews, e.g. (Weltevrede et al., 2016). Because the frequency of 
CMV-infected individuals increases with age (in industrialized coun-
tries) (Hecker et al., 2004) and socioeconomic factors influence the 
number of infected people at any age (Dowd et al., 2009), CMV infection 
can confound the age-effects on immune and other parameters such as 
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glucose regulation (Chen et al., 2012) leading to spurious associations 
with age. Notwithstanding the different living conditions in low- and 
middle-income countries (LMICs), the universality of these findings is 
reflected in reports that loss of CD8+ naïve cells may occur at an earlier 
chronological age in LMICs, presumably due to high pathogen burden 
and 100 % penetrance of CMV infection (Alam et al., 2013). 
Despite differences in many immune parameters between men and 
women, in the few studies examining this issue, the markedly lower 
levels of circulating CD8+ naïve T cells have been found in both sexes, 
further emphasising the universality of these findings (Di Benedetto 
et al., 2015). Intriguingly, although present, age-associated differences 
for CD4+ naïve T cells, B cells, and many aspects of innate immunity, 
especially dendritic cells (DCs) and neutrophils (Stervbo et al., 2015a; 
Stervbo et al., 2015b), are much less marked than for CD8 + T cells, one 
of the enduring mysteries in immunosenescence research. Again, it 
should be emphasized that the majority of immune cells resides in tis-
sues and not in blood, and that the latter most likely does not reflect 
patterns of cell subset distribution elsewhere (Thome and Farber, 2015). 
To reflect patterns of cell subset distribution in tissues with aging, 
ongoing technical developments in single-cell RNA sequencing are 
becoming a powerful tool, reflecting changes of cell-type composition 
within a tissue, and also comparing changes between organs. Moreover, 
this unbiased technology will provide an age-related transcriptomic 
profile of each cell subset. Combined with immunostaining and lineage 
tracing, it will also provide information on whether immune cells 
infiltrate or expand locally in the tissue. These new techniques promise 
exciting future discoveries, but so far, the few data on immune cell 
distribution in tissues in younger and older people are still too limited to 
be able to suggest any firm correlates with ageing, although pioneering 
work examining the distribution of immune cells in different organs 
post-mortem has revealed marked differences between blood and tissues 
(Thome et al., 2014; Dogra et al., 2020; Thome et al., 2016). However, 
we must still accept that for the bulk of thus-far available data, we have 
to rely on blood biomarkers, and that any mechanistic interpretations of 
their biological impact can only be hypothetical. An exception to this 
statement would be the important pioneering work on skin immune 
reactions in older adults (Akbar et al., 2013) which is being very 
informative in illustrating differences between in situ immune reactivity 
in younger and older adults (Vukmanovic-Stejic et al., 2018). In that 
study, antigen challenge locally in the skin was employed to investigate 
differences in tissue-specific mechanisms responsible for lower re-
sponses to virus in older adults, showing lower T-cell infiltration and 
increased sterile inflammation. This excessive inflammation locally in 
the skin early after antigen challenge inhibited antigen-specific immu-
nity. The application of this type of approach to questions of immune 
dysfunction in the elderly remains rare so far. 
4. Longitudinal studies allow individual changes over time to be 
mapped 
Longitudinal follow-up studies are required to establish change over 
time and associate immune biomarkers of ageing with robust clinical 
outcomes. The selection of these outcomes is challenging, with all-cause 
mortality the most robust but less informative than, for example, 
response to vaccination. As the latter is most commonly studied for 
influenza, many confounding factors complicate interpretations. 
Response to vaccination are considered below (see Section 5). In this 
section we will consider the clear endpoint of mortality and the less well- 
defined endpoints of morbidity and age-associated disease as proxies for 
ageing. Clearly, factors influencing these outcomes are not likely to be 
exclusively immune-related, and this is reflected in the inclusion of a 
multitude of variables in more recently-planned longitudinal studies, 
such the Baltimore Longitudinal Study on Aging, the Stanford cohort, 
the Berlin BASE-II study, the BELFRAIL study, the Newcastle 85-Plus 
study, the Leiden 85-Plus study and others. Indeed, the earliest studies 
were mostly designed to ask questions unrelated to immunology, onto 
which some immunological assessments were retrospectively bolted – 
this was the case with the pioneering Swedish OCTO/NONA studies. The 
latter established that a constellation of simple immunological mea-
surements, but not any single one by itself, was informative for 2-, 4-, 
and 6-year survival on follow-up of people 85 years old at baseline 
(Wikby et al., 1994; Ferguson et al., 1995). This so-called “Immune Risk 
Profile, IRP” (Pawelec et al., 2001) included poor T-cell proliferative 
responses to mitogens, high CD8 + T cell numbers and percentages, and 
low CD4 + T cells and CD19 + B cells. The study included resampling at 
these two-year intervals and tracked changes to the IRP over time, 
revealing that individuals who acquired the IRP showed increased 
mortality over the next two-year period (Wikby et al., 1998). The IRP 
was associated with CMV-seropositivity (Olsson et al., 2000) and the 
accumulation of late-stage differentiated CD8 + T cells that had lost 
expression of CD27 and CD28 (positive costimulatory receptors), and 
gained expression of KLRG-1 (with negative costimulatory function) and 
CD57, normally expressed by natural killer cells (Ouyang et al., 2003). 
Many of these cells were specific for CMV antigens, and the number of 
such clonal CD8 + T expansions was directly related to the survival time 
at very old age (Hadrup et al., 2006), underlining the importance of 
these cells with a “senescent” phenotype in facilitating continued sur-
vival of these oldest-old subjects. These studies were also important in 
illustrating that the IRP was in fact a relative weak predictor of survival, 
compared to higher levels of IL 6 in the blood, which was associated with 
cognitive impairment as measured by standard tests and formed a 
cluster more closely associated with mortality (Wikby et al., 2006). 
Strikingly, individuals with both this “inflammageing” phenotype and 
the IRP had much worse survival than those with either one or none of 
them. Therefore, at least in this population, inflammageing and immu-
nosenescence are separable. It was notable, if initially unexpected, that 
neither absolute values nor percentages of naïve CD8 + T cells were 
associated with mortality in these Swedish studies. This was also found 
to be the case in limited analyses in the Leiden 85-Plus study, where a 
paucity of naïve cells had no effect on 8-year survival – but higher levels 
of CD8 + T cells reacting to CMV antigens with a predominantly 
pro-inflammatory response were strongly correlated with survival time 
(Derhovanessian et al., 2013). Rather than being senescent, such cells 
may be critical for continued survival, a point reinforced very recently 
by the description of so-called “inflammescent” cells driven by CMV 
(Morris et al., 2020). This is yet another clear example of factors which 
can be associated with either positive or negative outcomes, depending 
on the circumstances and could be an illustration of the general finding 
that immunity is a dangerous ally. These results are consistent with the 
notion that immune control of persistent CMV infection was paramount 
in these very elderly people, but both the Swedish and the Dutch studies 
were conducted on very small numbers of people and the general-
isability of these findings is uncertain. Larger studies such as the 
BELFRAIL study revealed that 3-year survival on follow-up of 85-year--
old Belgians was greater in women who were CMV-seropositive and 
showed accumulations of late-stage CD8 + T cells as reflected in a CD4:8 
ratio <1. Strikingly, none of these parameters had any relevance for 
survival of men (Adriaensen et al., 2017). Thus, in marked disagreement 
to data reported elsewhere, here an IRP was defined in 
CMV-seronegative women (only) with a CD4:8 ratio >5, which was due 
to accumulations of CD4+ naïve cells. These data offer a striking illus-
tration of marked differences in different populations, or perhaps more 
likely, in different birth cohorts (end of the 19th century-vs-first quarter 
of the 20th). However, these studies were not able to include a survey of 
other factors which were shown to have a stronger association with 
mortality in the Swedish studies, namely markers of inflammation such 
as IL 6, often taken as a surrogate for “inflammageing”. Hence, exam-
ining immunological (and other) variables with a broader brush may 
yield less context-sensitive inconsistent results. Such studies are 
ongoing, including one recently published on the Stanford Clinical and 
Translational Research Unit Cohort (Alpert et al., 2019). This seminal 
study took a “multi-omics” approach to analyse immune parameters at 
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baseline and in younger and older adults who were reanalysed every 
year over a 9 follow-up. This approach encompassing expression of 
immune-related genes captured changes over time of a much wider 
range of parameters which were correlated with overall survival. As 
with the much more limited protein-level analysis in the Swedish studies 
(Nilsson et al., 2003), an immune signature (“IMM-AGE”) emerged 
which was surprisingly independent of exact chronological age or 
health/disease statuses, with the rapidity of its change being indepen-
dent of age at baseline, and suggesting that it had already been “pre--
programmed” at that time (all participants were adults). This is 
consistent with the notion that the immune system is “programmed” 
prior to puberty by the local environment, primarily driven by “tribal” 
pathogen exposure local to the group. The approach taken in this paper 
by Alpert et al. identified those fixed parameters whose changing tra-
jectories with age may be important for health and survival mostly as 
those factors already identified in earlier studies. Thus far, the crucial 
importance of these signatures has been documented by its application 
to a completely different population, the Framingham Heart Study, 
where it was able to predict mortality more accurately than other 
established biomarkers in this extremely well-investigated cohort 
(Alpert et al., 2019). Moreover, although IMM-AGE did correlate to 
some extent with the well-established “DNA methylation clock” linked 
to chronological age (Bocklandt et al., 2011), its association with overall 
survival was far closer than that of methylation age. In this respect, it 
would be interesting to test additional DNA methylation clocks, e.g. 
those trained on age-related phenotypes and mortality. 
5. Impact of age on vaccination 
As noted, all-cause mortality or even disease-specific mortality is a 
clear clinical outcome but not very informative otherwise. Morbidity, 
assessed by frailty, would be an important alternative but is controver-
sial. Alternatively, responses to vaccination, exceedingly important for 
the elderly who often respond poorly, would be a very valuable end- 
point. Increasing the success of infectious disease vaccines for the 
elderly is of paramount importance, as starkly emphasized by the SARS- 
CoV-2 pandemic currently raging during the preparation of this paper 
(Pawelec and Weng, 2020). CD8+ T cells are required for clearing 
virally-infected cells, but are those most affected in ageing. The CD4+ T 
helper cells (Czesnikiewicz-Guzik et al., 2008), antibody-producing B 
cells (Frasca, 2018), DCs that present antigen to T cells (Agrawal and 
Gupta, 2011), the lymph nodes in which this takes place (Thompson 
et al., 2017), are all also compromised to some degree in the ageing host. 
Many studies have focused on seasonal influenza due to its enormous 
public health impact, and currently of course on SARS-CoV-2. Here, a 
clear distinction must be made between vaccines intended to protect 
against neoantigens, which are generally less effective in the elderly, 
and those that boost waning memory responses, which can be highly 
effective in the elderly if given with an effective adjuvant. The latter are 
most impressively illustrated by the success of Shingrix, the Varicella 
Zoster vaccine against shingles (McElhaney et al., 2019). However, for 
new exposures, especially to newly-emerged pathogens such as 
currently SARS-CoV-2, because of the likelihood that most older people 
possess a narrowed T cell receptor repertoire due to a greatly reduced 
naïve T cell pool (Naylor et al., 2005; Egorov et al., 2018), it is 
conceivable that potential “holes in the repertoire” represent one of the 
biggest problems when the old immune system must face a new chal-
lenge. While this is likely to be true, at least in animal models (Yager 
et al., 2008) there is in fact surprisingly little published data on this in 
humans, but is likely to apply to us as well (Zhang et al., 2016). One 
study directly addressed the consequences in terms of clinically-relevant 
responses to vaccination against yellow fever (YF) and showed that 
differences in the CD4+ and CD8+ T cell response, and in DC function 
were associated with lower antibody titers (Schulz et al., 2015). This 
study measured recent thymic emigrants (RTEs) as a surrogate for the 
availability of naïve T cells and showed that lower numbers thereof were 
associated with poorer responses. Importantly, this study not only sup-
ports the expected result that fewer naïve cells presents a problem for 
combatting pathogens to which the individual was not previously 
exposed, but also points to what might be crucial inter-individual dif-
ferences (Tosi et al., 1982) in the residual RTE output from the remnant 
thymus at late life. 
The impact of donor immune age on influenza vaccination is 
complicated to dissect for many reasons, primarily due to the emergence 
of different seasonal strains of the virus, and the different levels of T cell 
memory depending on past exposures (McElhaney et al., 2020). Addi-
tional complications arise from the manner in which responder or 
non-responder status is assigned. For practical reasons, this is not usu-
ally done by measuring the degree of protection, but by the unreliable 
surrogate of post-vaccination changes in antibody titer. It may some-
times be the case that the presence of an already-high titer in an indi-
vidual cannot be further increased and, although it may be protective, 
this results in the classification of that individual as a “non-responder” 
(Mosterin Hopping et al., 2016a). This may already account for some of 
the discrepancies in the literature regarding the ability of the elderly to 
respond – as pointed out in a recent study concluding that older adults 
actually responded similarly to younger ones (Mosterin Hopping et al., 
2016b). However, T-cell-mediated responses as well as antibody re-
sponses are required for protection, and when these are measured 
instead of solely antibody levels, the common finding is that fewer older 
adults are able to mount a potentially protective T cell response. Failure 
to respond may be more likely in those infected with CMV (McElhaney 
et al., 2016). Moreover, in this respect, many of the accumulated CD8+
memory T cells in elderly people may exert stronger immunopatholog-
ical effects, possibly as the price to pay for the absolute requirement to 
maintain CMV-immunosurveillance. At least some of these late-stage 
differentiated CD27-CD28-CD57+KLRG-1+CD8+ T cells with short 
telomeres and little clonal proliferative capacity may indeed be mal-
adaptive – or alternatively, they may be a “necessary evil” to keep CMV 
in check. As “inflammescent” cells (Morris et al., 2020) they may 
contribute to the senescence-associated secretory profile (SASP), uni-
versally reviled as the cause of “inflammageing” (but of course, as with 
all things in biology, having its pros and cons). As a final point, it may be 
useful to consider what exactly is meant by “inflammageing” in 
contradistinction to “immunosenescence” because as mentioned above 
sometimes the terms seem to be used interchangeably. Inflammageing 
usually refers to the slightly higher levels of serum inflammatory factors 
commonly seen in older adults relative to the young, in individuals 
without overt infectious disease. It must be borne in mind that most 
data, as with immune cells, are derived from the systemic circulation 
and therefore represent only a biomarker. Moreover, it is likely the 
balance of pro- and anti-inflammatory factors that reflects the in-
dividual’s overall status (Morrisette-Thomas et al., 2014). Associations 
of higher levels of pre-inflammatory cytokines like IL 6 have been linked 
to frailty and mortality (Michaud et al., 2013) as well as inhibited im-
mune function, and efforts to block inflammageing without causing 
global immunosuppression are being actively considered and trialed 
(Chambers and Akbar, 2020). The relationships of these factors to im-
munity, however, are not clear. Their origin is not necessarily immune 
cells or exclusively immune cells, but it is perhaps more likely that they 
could be part of the SASP produced by senescent non-immune cells 
(Tchkonia et al., 2013). Hence, focusing on causality consistently places 
inflammageing in the foreground as the postulated direct agency of 
degenerative changes in many or most organ systems, including immune 
systems. The latter also face the compromise imposed by thymic invo-
lution which may be a crucial event for conservation of resources under 
hunter-gatherer conditions. The critical balance between the energeti-
cally expensive and potentially unreliable ally of adaptive immunity and 
its necessity for protecting against infection early in life is exemplified 
by findings that, for example, growth retardation in Amazonian children 
paralleled by inflammatory status is the price that must be paid for 
dealing with high pathogen loads in humans (Urlacher et al., 2018). 
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Finally, an additional reason for the poorer responses to vaccination 
in older adults may be the general slowdown in metabolism, prolifera-
tion, and information processing with age, a general manifestation of 
aging processes and not specific to the immune system. Nonetheless, it 
may contribute to slower immune responses and longer healing process 
in the old compared to the young, which in turn may contribute to both 
immunosenescence and decline in the ability to recover (resilience) 
eventually increasing mortality risk with age and limiting longevity 
(Ukraintseva et al., 2016). 
6. Conclusions 
Immune parameters assessed in cross-sectional studies clearly 
document multiple differences between younger and older populations. 
Animal studies as well as some more limited longitudinal studies in 
humans indicate that many of these differences are indeed likely to be 
intra-individual age- and environment-associated changes. Some im-
mune signatures established as subject to distinct changes with age can 
be associated with important health outcomes such as frailty and re-
sponses to vaccination, and finally, with mortality. Many others are 
clearly hallmarks of the adaptation to exposures over the lifespan and 
continue to play a positive role in maintaining organismal integrity. 
Many may be informative only in the population in which they were 
assessed, and the search for truly universal age-associated changes in 
immune markers is ongoing. Whether these exist as reflections of ageing 
processes per se is open to question (Waaijer et al., 2019). Thus far, they 
mostly seem limited to reductions in numbers, proportions and the an-
tigen receptor repertoire of peripheral blood naïve T cells and other 
immune cells. In turn, this reflects thymic involution at puberty and the 
degree of residual thymic function in later life, as well as possibly 
dysfunctional haematopoiesis (Leins et al., 2018) and the poorly defined 
detrimental systemic milieu in older individuals which remains myste-
rious (Ashapkin et al., 2020). Generating multidimensional immune 
signatures (Alpert et al., 2019) and incorporating multiple additional 
fields (Belsky et al., 2015) into constellations of markers may eventually 
lead to the development of an immunosenescence phenotype “IMP” that 
would be clinically-relevant and generalizable across different birth 
cohorts in different environments influencing the multiple immune 
system compensatory mechanisms (e.g. homeostatic proliferation, 
memory stem cells, anti-inflammatory mechanisms) which are impor-
tant for counteracting some of the putative age-associated changes. 
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